Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
- PMID: 19001608
- PMCID: PMC3299208
- DOI: 10.1093/jnci/djn367
Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
Comment on
-
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. doi: 10.1093/jnci/djn019. Epub 2008 Feb 26. J Natl Cancer Inst. 2008. PMID: 18314477 Free PMC article.
References
-
- Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675–683. - PubMed
-
- Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88(10):2283–2289. - PubMed
-
- Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006;119(10):2372–2375. - PubMed
